Header Logo

Connection

LEO LUZNIK to Recurrence

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Recurrence.
LEO LUZNIK
Connection Strength
0.943
Recurrence
  1. Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight. Blood Rev. 2023 11; 62:101093.
    View in: PubMed
    Score: 0.161
  2. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
    View in: PubMed
    Score: 0.146
  3. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 02; 102(2):391-400.
    View in: PubMed
    Score: 0.102
  4. Are alternative donors really still "alternative?". Biol Blood Marrow Transplant. 2014 Oct; 20(10):1463-4.
    View in: PubMed
    Score: 0.088
  5. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age =55 Years. Transplant Cell Ther. 2023 03; 29(3):182.e1-182.e8.
    View in: PubMed
    Score: 0.039
  6. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 03; 29(3):208.e1-208.e6.
    View in: PubMed
    Score: 0.039
  7. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control. 2002 Mar-Apr; 9(2):123-37.
    View in: PubMed
    Score: 0.037
  8. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
    View in: PubMed
    Score: 0.035
  9. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
    View in: PubMed
    Score: 0.031
  10. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019 04; 25(4):603-611.
    View in: PubMed
    Score: 0.030
  11. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018 05; 24(5):1099-1102.
    View in: PubMed
    Score: 0.028
  12. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 06; 24(6):1274-1280.
    View in: PubMed
    Score: 0.028
  13. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 04; 24(4):666-677.
    View in: PubMed
    Score: 0.028
  14. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
    View in: PubMed
    Score: 0.024
  15. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
    View in: PubMed
    Score: 0.024
  16. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2115-2122.
    View in: PubMed
    Score: 0.023
  17. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014 Mar; 20(3):314-8.
    View in: PubMed
    Score: 0.021
  18. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
    View in: PubMed
    Score: 0.016
  19. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar; 43(6):477-80.
    View in: PubMed
    Score: 0.015
  20. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87.
    View in: PubMed
    Score: 0.015
  21. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr; 12(4):414-21.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.